An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Emgality

Chemical Namegalcanezumab-gnlm
Dosage FormInjection (subcutaneous; 120 mg, 300 mg)
Drug ClassMonoclonal antibodies
SystemNervous
CompanyEli Lilly and Company
Approval Year2018

Indication

  • The prevention of migraines in adults.
Last updated on 11/11/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Emgality (Galcanezumab-gnlm) Prescribing Information 2018Eli Lilly and Company, Indianapolis, IN
Document TitleYearSource
Galcanezumab in migraine prevention: A systematic review and meta-analysis of randomized controlled trials. 2020Therapeutic Advances in Neurological Disorders
Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis. 2020BMC Neurology
Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta‑analysis. 2020Journal of Neurology
CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data. 2019Cephalalgia
Document TitleYearSource
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.2019The Journal of Headache and Pain